GIST

Use of new systemic adjuvant therapy in gastrointestinal tumors increasing

Use of new systemic adjuvant therapy in gastrointestinal tumors increasing

By

Use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time and patients treated with the therapy have improved survival over surgery alone, according to study data.

Adjuvant imatinib promising for failure-free survival in GIST

By

Adjuvant imatinib impacts short-term free from relapse in patients with localized, surgically resected, high/intermediate-risk gastrointestinal stromal tumors (GIST), according to interim results of an intergroup trial.

FDA approves Stivarga for GI stromal tumors

FDA approves Stivarga for GI stromal tumors

Regorafenib approved for inoperable or metastatic gastrointestinal stromal tumors.

Targeted drug overcomes resistance in patients with rare sarcoma

By

Regorafenib, a new, targeted, oral drug, demonstrated the ability to control metastatic GIST, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.

The role of sunitinib in the treatment of GIST

The role of sunitinib in the treatment of GIST

What is the role of sunitinib malate in the treatment of sarcomas?

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs